Efficacy of mobocertinib in patients previously treated with TKIs

Real-World Comparison Assesses Mobocertinib in NSCLC With EGFR Exon 20Подробнее

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicityПодробнее

Current treatments and challenges for patients with EGFR exon 20 insertion-positive NSCLCПодробнее

ZENITH20-4: efficacy & safety of poziotinib in treatment-naïve NSCLC with HER2 exon 20 mutationsПодробнее

Positive Data Announced for EGFR-mutant NSCLCПодробнее

TKIs to treat EGFRm-positive NSCLCПодробнее

EGFR TKIs for Upfront Treatment of NSCLCПодробнее

Mobocertinib for previously treated NSCLC with EFGR mutationsПодробнее

Dr Mok on the Efficacy of Taletrectinib in ROS1+ NSCLCПодробнее

Poziotinib in Treatment-Naïve NSCLC With HER2 Exon 20 MutationsПодробнее

Amivantamab and Mobocertinib: Side Effects and Treatment Timing - Lung CancerПодробнее

ASCO 2021 Lung Recap: Amivantamab and Mobocertinib for EGFR Exon 20Подробнее

Amivantamab and Mobocertinib for EGFR Exon-20 Disease - Lung Cancer Video LibraryПодробнее

The evolving treatment landscape for NSCLC with EGFR exon 20 insertion mutationsПодробнее

Recent approvals in the NSCLC treatment landscapeПодробнее

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLCПодробнее

NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over ChemotherapyПодробнее

ZENITH20: Poziotinib efficacy and safety in NSCLCПодробнее

Dr. Horn on the Role of Mobocertinib in NSCLCПодробнее